Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Kalkine 0
countryflagAU

Immutep Ltd

Healthcare AU IMM

0.24AUD
-(-%)

Last update at 2025-07-02T06:10:00Z

Day Range

0.240.24
LowHigh

52 Week Range

0.220.41
LowHigh

Fundamentals

  • Previous Close 0.24
  • Market Cap349.34M
  • Volume531285
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-48.73924M
  • Revenue TTM4.88M
  • Revenue Per Share TTM0.004
  • Gross Profit TTM -41.56212M
  • Diluted EPS TTM-0.03

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -39.89635M -32.21079M -29.90259M -13.46819M -18.34398M
Minority interest - - - - -
Net income -39.89635M -32.21083M -29.90262M -13.46823M -16.27064M
Selling general administrative 8.68M 7.21M 6.28M 6.34M 6.13M
Selling and marketing expenses - - - - -
Gross profit - 0.17M - 7.49M 0.14M
Reconciled depreciation - 3.00M - 2.08M 1.88M
Ebit -41.43131M -33.93755M -19.56058M -16.01888M -20.41733M
Ebitda - -31.87409M -20.72271M -13.93924M -18.53818M
Depreciation and amortization - 2.06M -1.16213M 2.08M 1.88M
Non operating income net other - - - - -
Operating income -40.63135M -33.93755M -19.56058M -16.01888M -20.41733M
Other operating expenses - 34.01M 19.66M 22.56M 19.10M
Interest expense 0.02M 0.09M 0.00983M 0.01M 0.00000M
Tax provision 0.00000M 0.00005M 0.00003M 0.00004M 0.00000M
Interest income 0.74M 0.33M 0.11M 1.40M 0.46M
Net interest income 0.92M 0.19M 0.10M 0.19M 0.40M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - 0.00003M 0.00003M 0.00004M -2.07334M
Total revenue 1.13M 0.17M 0.42M 7.49M 0.14M
Total operating expenses 41.43M 34.01M 19.66M 22.56M 19.10M
Cost of revenue - - - - 16.59M
Total other income expense net 0.62M 1.73M -10.34201M 2.55M 2.07M
Discontinued operations - - - - -
Net income from continuing ops -39.89635M -46.82423M -29.90262M -13.46823M -18.34398M
Net income applicable to common shares -39.89635M -32.21083M -29.90262M -13.46823M -18.34398M
Preferred stock and other adjustments - - - - -
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Total assets 201.58M 147.45M 102.17M 82.03M 46.60M
Intangible assets 8.13M 9.38M 10.44M 12.74M 15.08M
Earning assets - - - - -
Other current assets - 0.05M 3.55M 2.17M 1.44M
Total liab 12.06M 10.98M 8.09M 8.76M 13.30M
Total stockholder equity 189.52M 136.47M 94.08M 73.27M 33.30M
Deferred long term liab - - - - -
Other current liab - 4.14M 3.37M 3.31M 1.60M
Common stock - 446.27M 367.41M 313.42M 242.99M
Capital stock 542.11M 446.27M 534.09M 313.42M 242.99M
Retained earnings -382.64716M -339.93053M -302.33521M -274.64222M -275.70606M
Other liab - 0.16M 0.12M 0.81M 1.01M
Good will 0.11M 0.11M 0.11M 0.11M 0.11M
Other assets - 2.52M 0.50M 0.45M -
Cash 161.79M 123.42M 80.00M 60.13M 26.32M
Cash and equivalents - 3.59M 0.30M 8.28M 13.53M
Total current liabilities 10.49M 9.77M 6.41M 5.34M 3.36M
Current deferred revenue - - - - -
Net debt - -122.18945M -78.26131M -57.31301M -17.27055M
Short term debt - 0.19M 0.17M 0.21M 0.13M
Short long term debt - - - - -
Short long term debt total - 1.23M 1.73M 2.82M 9.05M
Other stockholder equity - 6.43M 5.43M 44.15M 75.68M
Property plant equipment - 0.47M 0.31M 0.31M 0.25M
Total current assets 191.35M 134.97M 90.81M 68.42M 31.15M
Long term investments - - - - -
Net tangible assets - 126.98M 83.52M 60.42M 18.10M
Short term investments 20.09M - - - -
Net receivables 0.00524M 7.97M 8.37M 6.12M 3.39M
Long term debt 0.96M 0.84M 2.11M 2.53M 8.79M
Inventory - - -1.10832M - -
Accounts payable 3.79M 5.45M 2.87M 1.82M 1.64M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 30.13M 29.00M 34.49M 66.01M
Additional paid in capital - - - - -
Common stock total equity - - - - 242.99M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 2.52M 0.50M 0.45M -
Deferred long term asset charges - - - - -
Non current assets total 10.23M 12.48M 11.36M 13.61M 15.45M
Capital lease obligations 0.63M 0.39M 0.41M 0.29M 0.26M
Long term debt total - 1.04M 1.56M 2.61M 8.92M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -0.03100M -0.04500M -0.02400M -0.01900M -0.04143M
Change to liabilities 3.27M 1.44M 1.38M -2.12600M 1.40M
Total cashflows from investing activities -0.08274M -0.02291M -0.01560M -0.01935M -0.04143M
Net borrowings -0.21197M -0.22254M -0.21438M -0.07754M -0.07754M
Total cash from financing activities 76.04M 50.33M 52.68M 20.48M 8.01M
Change to operating activities -0.90011M -0.74727M -0.54342M 0.32M 0.02M
Net income -39.89635M -32.21083M -29.90262M -13.46823M -18.34398M
Change in cash 43.42M 19.40M 34.27M 9.75M -6.90754M
Begin period cash flow 80.00M 60.59M 26.32M 16.57M 23.48M
End period cash flow 123.42M 80.00M 60.59M 26.32M 16.57M
Total cash from operating activities -35.88300M -30.22975M -17.64034M -10.83934M -15.28640M
Issuance of capital stock 80.08M 52.98M 43.31M 22.03M 4.87M
Depreciation 2.06M 2.06M 2.07M 2.08M 1.88M
Other cashflows from investing activities - - - - -
Dividends paid 0.00000M 0.00000M - 0.00000M -
Change to inventory - - - - -
Change to account receivables -1.60770M -2.24938M -2.83054M 1.90M -1.76213M
Sale purchase of stock 80.08M 52.98M 54.57M 22.03M 8.79M
Other cashflows from financing activities -3.85600M -2.42715M 9.59M -1.47493M 3.14M
Change to netincome 1.71M 1.48M 12.18M 0.46M 1.29M
Capital expenditures 0.05M 0.02M 0.02M 0.02M 0.04M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 4.66M -1.56119M 1.75M 8.26M 4.27M
Stock based compensation - 1.49M - - -
Other non cash items - -0.00804M 29.90M 11.39M 16.46M
Free cash flow -35.93000M -30.25267M -17.65594M -10.85869M -15.32783M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
IMM
Immutep Ltd		 - -% 0.24 - 7.50 71.60 2.07 994.70 -4.4207
CSL
CSL Ltd		 1.53 0.64% 239.77 28.55 32.05 7.64 4.03 5.80 18.01
TLX
Telix Pharmaceuticals Ltd		 0.68 2.83% 24.75 177.75 56.82 10.64 14.57 10.40 88.05
MSB
Mesoblast Ltd		 -0.165 8.97% 1.68 - 454.55 369.57 2.90 67.90 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 -0.25 1.75% 14.00 12.99 78.12 8.25 4.61 7.03 8.53

Reports Covered

Stock Research & News

View All

Profile

Immutep Limited, a late-stage biotechnology company, engages in developing novel LAG-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alpha (efti or IMP321), a soluble LAG-3lg fusion based, which is in clinical development for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. In addition, it develops INSIGHT-003, which is in phase I to treat 1L NSCLC and solid tumors; INSIGHT-005, which is in phase I to treat metastatic urothelial cancer; IMP761, which is in preclinical trial to treat autoimmune disease; and IMP731 and IMP701 which is in clinical development. Further, the company develops LAG525, which is in phase II clinical trial to treat solid tumors and blood cancer, triple negative breast cancer, and melanoma; and in phase I to treat triple negative breast cancer. Immutep has collaboration with Merck & Co., Inc., GlaxoSmithKline, EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.

Immutep Ltd

Australia Square, Sydney, NSW, Australia, 2000

Key Executives

Name Title Year Born
Mr. Marc Voigt CEO, MD, CFO, Chief Bus. Officer & Exec. Director 1973
Ms. Deanne Miller LLB COO, Gen. Counsel & Joint Company Sec. 1977
Dr. Frederic Triebel M.D., Ph.D. Chief Scientific Officer, Chief Medical Officer & Exec. Director 1955
Ms. Indira Naidu Joint Company Sec. NA
Mr. Christian Mueller Director of Clinical Devel. & Regulatory Affairs NA
Mr. Shengfei Fang Fin. Director & Assistant Company Sec. NA
Mr. Marc Voigt CEO, MD, CFO, Chief Business Officer & Executive Director 1973
Ms. Deanne Miller LLB COO, General Counsel & Joint Company Secretary 1977
Dr. Frederic Triebel M.D., Ph.D. Chief Scientific Officer & Executive Director 1955
Mr. Marc Voigt CEO, MD, CFO, Chief Business Officer & Executive Director 1973

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.